CLIFFSIDE LABS

Address: 579 Bergen Blvd, Ridgefield, NJ 07657
CLIA Code: 31D2096452
Lab Director: Dr. Hua Chen
Phone No. : 201-945-3467 | Fax: 201-945-3425

PLEASE SUBMIT THE FOLLOWING WITH REQUISITION FORM

- ☐ Statement of Medical Necessity (Signed by Physician)
- ☐ Informed Consent Form (Signed by Pt & Physician)
- ☐ SOAP & Progress Note (Signed by Physician)
- ☐ Summary of Active Medications
- ☐ Scanned Insurance Card Copy

TESTING REQUISITION FORM - THYROID GENETIC DISEASE

PATIENT INFORMATION

Patient First Name	Patient Last Name	Biological Sex ☐ F ☐ M
Date of Birth (MM/DD/YYYY)	Phone Number	Email Address
Address	City	State / Zip

Ethnicity: ☐ African American ☐ Asian ☐ Caucasian ☐ Hispanic ☐ Jewish(Ashkenazi) ☐ Portuguese ☐ Other

PATIENT INSURANCE INFORMATION

☐ Insurance ☐ Self-Pay ☐ Client Bill

Name of the insurance	Secondary Insurance, If any
Insurance Policy/ID number	Name of the insured
Insurance Group number	Date of Birth of Insured

SPECIMEN INFORMATION

Date Sample Collected (mm/dd/yy) (required)

Medical Record#

☐ Buccal Swab

☐ Other (specify source)

ORDERING PHYSICIAN/SENDING FACILITY (Each Listed person will receive a copy of the report)

Facility Name (Facility Code):	Address:	City:	
State/Country :	Zip:	Phone:	
Ordering Licensed Provider Name (Last, First)(Code)	NPI#	Phone	Fax/Email

STATEMENT OF MEDICAL NECESSITY

By submission of this test requisition and accompanying sample(s), I: (i) authorize and direct to perform the testing indicated; (ii) certify that the person listed as the ordering provider is authorized by law to order the test(s) requested; (iii) certify that any custom panel and/or ordered test(s) requested on this test requisition form are reasonable and medically necessary for the diagnosis and/or treatment of a disease, illness, impairment, symptom, syndrome or disorder; (iv) the test results will determine my patient's medical management and treatment decisions of this patient's condition on this date of service; (v) have obtained this patient's and relatives', when applicable, written informed consent to undergo any genetic testing requested; and (vi) that the full and appropriate diagnosis code(s) are indicated to the highest level of specificity.

Signature of Provider (required) Date:

INDICATIONS FOR TESTING (CHECK ALL THAT APPLY)

☐ Diagnostic ☐ Family history ☐ Positive or normal control ☐ Other.....

Will Patient management be changed depending on the test results? ☐ Yes ☐ No

CLINICAL PRESENTATION

Please indicate any clinical presentations and /or findings that may be relavant to genetic testing:

- Behavior
- Conditions
- Pedigree/Family History
- Phenotypes
- Physical
- Symptoms

There are many presentations which may not seem like a direct association for disease. Please List the most suspected presentations and attach detailed medical records and/or pedigree.

Custom Thyroid Genetic Disease Panel (Select the genes below) or (checkbox) ☐ Comprehensive Thyroid Genetic Disease Panel (Test All Genes)

☐ PIK3CA	☐ SLC5A5	☐ PAX8	☐ TGFBI	☐ ATP1A2	☐ PLN	☐ IRAK1	☐ CST3
☐ TRH	☐ CACNA1A	☐ GLIS3	☐ TG	☐ HRAS	☐ TFR2	☐ G6PD	☐ CST1
☐ THRB	☐ PRKCG	☐ FOXE1	☐ THRA	☐ TTR	☐ SLC26A4	☐ SLC16A2	☐ CSTB
☐ CTNNB1	☐ HAMP	☐ SECISBP2	☐ TP53	☐ IYD	☐ TSHR	☐ IGSF1	☐ DUOX2
☐ KRAS	☐ SLC40A1	☐ GNAQ	☐ TSHB	☐ HFE	☐ NKX2-1	☐ TBL1X	
☐ DUOX1	☐ TPO	☐ PLCG2	☐ NRAS	☐ ESR1	☐ MECP2	☐ IRS4	

INDICATION (S) FOR TESTING — ICD-10 Codes

Category - 1: ICD10 codes

- ☐ E06.0 Acute thyroiditis
- ☐ E06.1 Subacute thyroiditis
- ☐ E06.2 Chronic thyroiditis with transient thyrotoxicosis
- ☐ E06.3 Autoimmune thyroiditis
- ☐ E06.4 Drug-induced thyroiditis
- ☐ E06.5 Other chronic thyroiditis
- ☐ E06.9 Thyroiditis, unspecified
- ☐ E03.0 Congenital hypothyroidism with diffuse goiter
- ☐ E03.1 Congenital hypothyroidism without goiter
- ☐ E03.2 Hypothyroidism due to medicaments and other exogenous substances
- ☐ E03.3 Postinfectious hypothyroidism
- ☐ E03.4 Atrophy of thyroid (acquired)
- ☐ E03.5 Myxedema coma
- ☐ E03.8 Other specified hypothyroidism
- ☐ E03.9 Hypothyroidism, unspecified
- ☐ E01.0 Iodine-deficiency related diffuse (endemic) goiter
- ☐ E01.1 Iodine-deficiency related multinodular (endemic) goiter
- ☐ E01.2 Iodine-deficiency related (endemic) goiter, unspecified
- ☐ E01.8 Other iodine-deficiency related thyroid disorders and allied conditions
- ☐ E04.0 Nontoxic diffuse goiter
- ☐ E04.1 Nontoxic single thyroid nodule
- ☐ E04.2 Nontoxic multinodular goiter
- ☐ E04.8 Other specified nontoxic goiter
- ☐ E04.9 Nontoxic goiter, unspecified
- ☐ E05.00 Thyrotoxicosis with diffuse goiter without thyrotoxic crisis or storm
- ☐ E05.01 Thyrotoxicosis with diffuse goiter with thyrotoxic crisis or storm
- ☐ E05.10 Thyrotoxicosis with toxic single thyroid nodule without thyrotoxic crisis or storm
- ☐ E05.11 Thyrotoxicosis with toxic single thyroid nodule with thyrotoxic crisis or storm
- ☐ E05.20 Thyrotoxicosis with toxic multinodular goiter without thyrotoxic crisis or storm
- ☐ E05.21 Thyrotoxicosis with toxic multinodular goiter with thyrotoxic crisis or storm
- ☐ E05.30 Thyrotoxicosis from ectopic thyroid tissue without thyrotoxic crisis or storm
- ☐ E05.31 Thyrotoxicosis from ectopic thyroid tissue with thyrotoxic crisis or storm
- ☐ E05.40 Thyrotoxicosis factitia without thyrotoxic crisis or storm
- ☐ E05.41 Thyrotoxicosis factitia with thyrotoxic crisis or storm
- ☐ E05.80 Other thyrotoxicosis without thyrotoxic crisis or storm
- ☐ E05.81 Other thyrotoxicosis with thyrotoxic crisis or storm
- ☐ E05.90 Thyrotoxicosis, unspecified without thyrotoxic crisis or storm
- ☐ E05.91 Thyrotoxicosis, unspecified with thyrotoxic crisis or storm
- ☐ E07.0 Hypersecretion of calcitonin
- ☐ E07.1 Dyshormogenetic goiter
- ☐ E07.81 Sick-euthyroid syndrome
- ☐ E07.89 Other specified disorders of thyroid
- ☐ E07.9 Disorder of thyroid, unspecified
- ☐ E20.1 Pseudohypoparathyroidism
- ☐ Z85.8 Personal history of malignant neoplasms of other organs and systems
- ☐ D02.0 Carcinoma in situ of larynx
- ☐ D09.3 Carcinoma in situ of thyroid and other endocrine glands
- ☐ D14.1 Benign neoplasm of larynx

Category - 2: ICD10 codes

- ☐ C17.0 Malignant neoplasm of duodenum
- ☐ C17.1 Malignant neoplasm of jejunum
- ☐ C17.2 Malignant neoplasm of ileum
- ☐ C17.3 Meckel's diverticulum, malignant
- ☐ C17.8 Malignant neoplasm of overlapping sites of small intestine
- ☐ C17.9 Malignant neoplasm of small intestine, unspecified
- ☐ C18.0 Malignant neoplasm of cecum
- ☐ C18.1 Malignant neoplasm of appendix
- ☐ C18.2 Malignant neoplasm of ascending colon
- ☐ C18.3 Malignant neoplasm of hepatic flexure
- ☐ C18.4 Malignant neoplasm of transverse colon
- ☐ C18.5 Malignant neoplasm of splenic flexure
- ☐ C18.6 Malignant neoplasm of descending colon
- ☐ C18.7 Malignant neoplasm of sigmoid colon
- ☐ C18.8 Malignant neoplasm of overlapping sites of colon
- ☐ C18.9 Malignant neoplasm of colon, unspecified
- ☐ C19 Malignant neoplasm of rectosigmoid junction
- ☐ C20 Malignant neoplasm of rectum
- ☐ C21.0 Malignant neoplasm of anus, unspecified
- ☐ C21.1 Malignant neoplasm of anal canal
- ☐ C21.2 Malignant neoplasm of cloacogenic zone
- ☐ C21.8 Malignant neoplasm of overlapping of rectum, anus and anal canal
- ☐ C33 Malignant neoplasm of trachea
- ☐ C34.00 Malignant neoplasm of unspecified main bronchus
- ☐ C34.01 Malignant neoplasm of right main bronchus
- ☐ C34.02 Malignant neoplasm of left main bronchus
- ☐ C34.10 Malignant neoplasm of upper lobe, unspecified bronchus or lung
- ☐ C34.11 Malignant neoplasm of upper lobe, right bronchus or lung
- ☐ C34.12 Malignant neoplasm of upper lobe, left bronchus or lung
- ☐ C34.2 Malignant neoplasm of middle lobe, bronchus or lung
- ☐ C34.30 Malignant neoplasm of lower lobe, unspecified bronchus or lung
- ☐ C34.31 Malignant neoplasm of lower lobe, right bronchus or lung
- ☐ C34.32 Malignant neoplasm of lower lobe, left bronchus or lung
- ☐ C34.80 Malignant neoplasm of overlapping sites of unspecified bronchus and lung
- ☐ C34.81 Malignant neoplasm of overlapping sites of right bronchus and lung
- ☐ C34.82 Malignant neoplasm of overlapping sites of left bronchus and lung
- ☐ C34.90 Malignant neoplasm of unspecified part of unspecified bronchus or lung
- ☐ C34.91 Malignant neoplasm of unspecified part of right bronchus or lung
- ☐ C34.92 Malignant neoplasm of unspecified part of left bronchus or lung
- ☐ C38.4 Malignant neoplasm of pleura
- ☐ C45.0 Mesothelioma of pleura
- ☐ C45.1 Mesothelioma of peritoneum
- ☐ C48.1 Malignant neoplasm of specified parts of peritoneum
- ☐ C48.2 Malignant neoplasm of peritoneum, unspecified
- ☐ C48.8 Malignant neoplasm of overlapping retroperitoneum and peritoneum
- ☐ C54.0 Malignant neoplasm of isthmus uteri
- ☐ C54.1 Malignant neoplasm of endometrium
- ☐ C54.2 Malignant neoplasm of myometrium
- ☐ C54.3 Malignant neoplasm of fundus uteri
- ☐ C54.8 Malignant neoplasm of overlapping sites of corpus uteri
- ☐ C54.9 Malignant neoplasm of corpus uteri, unspecified
- ☐ C55 Malignant neoplasm of uterus, part unspecified
- ☐ C56.1 Malignant neoplasm of right ovary
- ☐ C56.2 Malignant neoplasm of left ovary
- ☐ C56.3 Malignant neoplasm of bilateral ovaries
- ☐ C56.9 Malignant neoplasm of unspecified ovary
- ☐ C57.00 Malignant neoplasm of unspecified fallopian tube
- ☐ C57.01 Malignant neoplasm of right fallopian tube
- ☐ C57.02 Malignant neoplasm of left fallopian tube
- ☐ C57.10 Malignant neoplasm of unspecified broad ligament
- ☐ C57.11 Malignant neoplasm of right broad ligament
- ☐ C57.12 Malignant neoplasm of left broad ligament
- ☐ C57.20 Malignant neoplasm of unspecified round ligament
- ☐ C57.21 Malignant neoplasm of right round ligament
- ☐ C57.22 Malignant neoplasm of left round ligament
- ☐ C57.3 Malignant neoplasm of parametrium

Continued

INDICATION (S) FOR TESTING — ICD-10 Codes

- ☐ C57.4 Malignant neoplasm of uterine adnexa, unspecified
- ☐ C73* Malignant neoplasm of thyroid gland
- ☐ C92.00 Acute myeloblastic leukemia, not having achieved remission
- ☐ C92.01 Acute myeloblastic leukemia, in remission
- ☐ C92.02 Acute myeloblastic leukemia, in relapse
- ☐ C92.10 Chronic myeloid leukemia, BCR/ABL-positive, not having achieved remission
- ☐ C92.11 Chronic myeloid leukemia, BCR/ABL-positive, in remission
- ☐ C92.12 Chronic myeloid leukemia, BCR/ABL-positive, in relapse
- ☐ C92.40 Acute promyelocytic leukemia, not having achieved remission
- ☐ C92.41 Acute promyelocytic leukemia, in remission
- ☐ C92.42 Acute promyelocytic leukemia, in relapse
- ☐ C92.50 Acute myelomonocytic leukemia, not having achieved remission
- ☐ C92.51 Acute myelomonocytic leukemia, in remission
- ☐ C92.52 Acute myelomonocytic leukemia, in relapse
- ☐ C92.60 Acute myeloid leukemia with 11q23-abnormality not having achieved remission
- ☐ C92.61 Acute myeloid leukemia with 11q23-abnormality in remission
- ☐ C92.62 Acute myeloid leukemia with 11q23-abnormality in relapse
- ☐ C92.A0 Acute myeloid leukemia with multilineage dysplasia, not having achieved remission
- ☐ C92.A1 Acute myeloid leukemia with multilineage dysplasia, in remission
- ☐ C92.A2 Acute myeloid leukemia with multilineage dysplasia, in relapse
- ☐ C93.10 Chronic myelomonocytic leukemia not having achieved remission
- ☐ C93.11 Chronic myelomonocytic leukemia, in remission
- ☐ C93.12 Chronic myelomonocytic leukemia, in relapse
- ☐ D34 Benign neoplasm of thyroid gland
- ☐ D44.0 Neoplasm of uncertain behavior of thyroid gland
- ☐ D44.2* Neoplasm of uncertain behavior of parathyroid gland
- ☐ D44.9 Neoplasm of uncertain behavior of unspecified endocrine gland
- ☐ D46.0 Refractory anemia without ring sideroblasts, so stated
- ☐ D46.1 Refractory anemia with ring sideroblasts
- ☐ D46.20 Refractory anemia with excess of blasts, unspecified
- ☐ D46.21 Refractory anemia with excess of blasts 1
- ☐ D46.22 Refractory anemia with excess of blasts 2
- ☐ D46.4 Refractory anemia, unspecified
- ☐ D46.9 Myelodysplastic syndrome, unspecified
- ☐ D46.A Refractory cytopenia with multilineage dysplasia
- ☐ D46.B Refractory cytopenia with multilineage dysplasia and ring sideroblasts
- ☐ D46.C Myelodysplastic syndrome with isolated del(5q) chromosomal abnormality
- ☐ D46.Z Other myelodysplastic syndromes
- ☐ E01.0 Iodine-deficiency related diffuse (endemic) goiter
- ☐ E01.1 Iodine-deficiency related multinodular (endemic) goiter
- ☐ E01.2 Iodine-deficiency related (endemic) goiter, unspecified
- ☐ E04.0 Nontoxic diffuse goiter
- ☐ E04.1 Nontoxic single thyroid nodule
- ☐ E04.2 Nontoxic multinodular goiter
- ☐ E04.8 Other specified nontoxic goiter
- ☐ E04.9 Nontoxic goiter, unspecified
- ☐ Z85.030 Personal history of malignant carcinoid tumor of large intestine
- ☐ Z85.038 Personal history of other malignant neoplasm of large intestine
- ☐ Z85.040 Personal history of malignant carcinoid tumor of rectum
- ☐ Z85.048 Personal history of other malignant neoplasm of rectum, rectosigmoid junction, and anus

Additional ICD-10 codes: .....

INFORMED CONSENT

For the purposes of this consent, "I", "my", and "your" will refer to me or to my child, including my unborn child, if my child is the person for whom the healthcare provider has ordered testing.

PURPOSE OF THIS TEST

The purpose of this test is (a) to see if I may have a genetic variant or chromosome rearrangement causing a genetic disorder; or (b) to evaluate the chance that I will develop or passon a genetic disorder in the future. If I already know the specific gene variant(s) or chromosome rearrangement that causes the genetic disorder in my family, I agree to inform the laboratory of this information.

WHAT TYPE OF TEST RESULTS CAN I EXPECT FROM GENETIC TESTING?

1. Positive: A change in your DNA was found, which is very likely the cause of your features/symptoms. This is the most straightforward test result, which can be used as the basis to test other family members to determine their chances of having either the disease or a child with the disease.

2. Negative: No variants were found to explain your symptoms. This does not mean that you do not have a genetic condition. It is still possible that there is a genetic variant not found by the test that was ordered. Your healthcare provider or genetic counselor may discuss more testing either now or in the future.

3. Variant of Uncertain Significance (VUS): A change in a gene was found. However, we are not sure whether this variant is the cause of your symptoms/features. More information is needed. We may suggest testing other family members to help figure out the meaning of the test result.

4. Unexpected Results: In rare instances, this test may reveal an important genetic change that is not directly related to the reason for ordering this test. For example, this test may find you are at risk for another genetic condition I am not aware of or it may indicate differences in the number or rearrangement of sex chromosomes. We may disclose this information to the ordering healthcare provider if it likely affects medical care. Because medical and scientific knowledge is constantly changing, new information that becomes available may supplement the information **Cliffside Labs** used to interpret my results.

Healthcare providers can contact **Cliffside Labs** at any time to discuss the classification of an identified variant.

WHAT IS TRIO/DUO-BASED GENETIC TESTING?

For some genetic tests, including samples from the biological parents and/or other biological relatives along with the patient's sample can help with the interpretation of the test results. These tests are often referred to as "trio tests" since they typically include samples from the patient and both parents. Samples from relatives should be submitted with the patient's sample. Clinical information must be provided for the patient and any relative who submits a sample.

I understand that **Cliffside Labs** will use the relative sample(s) when needed for the interpretation of my test results and that my test report may include clinical and genetic information abouta relative when it is relevant to the interpretation of the test results. I further understand that relatives will not receive an independent analysis of data nor a separate report.

RISKS AND LIMITATIONS OF GENETIC TESTING

1. In some cases, testing may not identify a genetic variant even though one exists. This may be due to limitations in current medical knowledge or testing technology.

2. Accurate interpretation of test results may require knowing the true biological relationships in a family. I understand that if I fail to accurately state the biological relationships in my family, it could lead to incorrect interpretation of the test results, incorrect diagnoses, and/or inconclusive test results. If genetic testing reveals that the true biological relationships in a family are not as I reported them, including non-paternity (the reported father is not the biological father) and consanguinity (the parents are related by blood), I agree to have these findings reported to the healthcare provider who ordered the test.

3. Although genetic testing is highly accurate, inaccurate results may occur. These reasons include, but are not limited to mislabeled samples, inaccurate reporting of clinical/medical information, rare technical errors, or other reasons.

4. I understand that this test may not detect all of the long-term medical risks that I might experience. The result of this test does not guarantee my health and that additional diagnostic tests may still need to be done.

5. I agree to provide an additional sample if the initial sample is not adequate.

PATIENT CONFIDENTIALITY AND GENETIC COUNSELING

It is recommended that I receive genetic counseling before and after having this genetic test. I can find a genetic counselor in my area at www.nsgc.org. Further testing or additional consultations with a healthcare provider may be necessary.

To maintain confidentiality, test results will only be released to the referring healthcare provider, the ordering laboratory, to me, to other healthcare providers involved in my care, diagnosis and treatment, or to others with my consent or as permitted or required by law. Federal laws prohibit unauthorized disclosure of this information. More information can be found at: www.genome.gov/10002077

INTERNATIONAL SAMPLES

If I reside outside the United States, I attest that by providing a sample for testing, I am not knowingly violating any export ban or other legal restriction in the country of my residence.

SAMPLE RETENTION

After testing is complete, my sample may be de-identified and be used for test development and improvement, internal validation, quality assurance, and training purposes. **Cliffside Labs** will not return DNA samples to you or to referring healthcare providers, unless specific prior arrangements have been made. I understand that samples from residents of New York State will not be included in the de-identified research studies described in this authorization and will not retain them for more than 60 days after test completion, unless specifically authorized by my selection. The authorization is optional, and testing will be unaffected if I do not check the box for the New York authorization language. **Cliffside Labs** will not perform any tests on the biological sample other than those specifically authorized.

DATABASE PARTICIPATION

De-identified health history and genetic information can help healthcare providers and scientists understand how genes affect human health. Sharing this de-identified information helps healthcare providers to provide better care for their patients and researchers to make new discoveries. **Cliffside Labs** shares this type of information with healthcare providers, scientists, and healthcare databases. **Cliffside Labs** will not share any personally identifying information and will replace the identifying information with a unique code not derived from any personally identifying information. Even with a unique code, there is a risk that I could be identified based on the genetic and health information that is shared. **Cliffside Labs** believes that this is unlikely, though the risk is greater if I have already shared my genetic or health information with public resources, such as genealogy websites.

EXOME/GENOME SEQUENCING SECONDARY FINDINGS

Applicable Only for Full Exome Sequencing and Genome Sequencing Tests. • Does not pertain to Xpanded® or Slice tests

As many different genes and conditions are analyzed in an exome or genome sequencing test, these tests may reveal some findings not directly related to the reason for ordering the test. Such findings are called "incidental" or "secondary" and can provide information that was not anticipated.

Secondary findings are variants, identified by an exome or genome sequencing test, in genes that are unrelated to the individual's reported clinical features.

The American College of Medical Genetics and Genomics (ACMG) has recommended that secondary findings identified in a specific subset of medically actionable genes associated with various inherited disorders be reported for all probands undergoing exome or genome sequencing. Please refer to the latest version of the ACMG recommendations for reporting of secondary findings in clinical exome and genome sequencing for complete details of the genes and associated genetic disorders. Reportable secondary findings will be confirmed by an alternate test method when needed.

WHAT WILL BE REPORTED FOR THE PATIENT? - All pathogenic and likely pathogenic variants associated with specific genotypes identified in the genes (for which a minimum of 10X coverage was achieved by exome sequencing or a minimum of 15X coverage was achieved by genome sequencing), as recommended by the ACMG.

WHAT WILL BE REPORTED FOR RELATIVES? - The presence or absence of any secondary finding(s) reported for the proband will be provided for all relatives analyzed by an exome or genome sequencing test.

LIMITATIONS - Pathogenic and/or likely pathogenic variants may be present in a portion of the gene not covered by this test and therefore are not reported. The absence of reportable secondary findings for any particular gene does not mean there are no pathogenic and/or likely pathogenic variants in that gene. Pathogenic variants and/or likely pathogenic variants that may be present in a relative, but are not present in the proband, will not be identified, or reported. Only changes at the sequence level will be reported in the secondary findings report. Larger deletions/duplications, abnormal methylation, triplet repeat or other expansion variants, or other variants not routinely identified by clinical exome and genome sequencing will not be reported.

FINANCIAL AGREEMENT AND GUARANTEE - For insurance billing, I understand and authorize **Cliffside Labs** to bill my health insurance plan on my behalf, to release any information required for billing, and to be my designated representative for purposes of appealing any denial of benefits. I irrevocably assign to and direct that payment be made directly to I understand that my out-of-pocket costs may be different than the estimated amount indicated to me by **Cliffside Labs** as part of a benefit investigation. I agree to be financially responsible for any and all amounts as indicated on the explanation of benefits issued by my health insurance plan. If my insurance provider sends a payment directly to me for services performed by **Cliffside Labs** on my behalf, I agree to endorse the insurance check and forward it to **Cliffside Labs** within 30 days of receipt as payment towards **Cliffside Labs** claim for services rendered.

MEDICARE

A completed Advance Beneficiary Notice (ABN) is required for Medicare patients.

DIGITAL PATIENT LETTER CONSENT

• Applicable Only for Commercial Insurance

• Estimate is provided by your health insurance company and therefore NO estimate will be sent for any orders placed with federal or state-funded insurance plans (e.g. Medicare, Medicaid, Tricare, etc.), institutional bill, or patient bill (self-pay).

To provide you with the estimated out-of-pocket expenses related to your test, **Cliffside Labs** will send you an email and/or text with the link to access your personalized Digital Patient Letter.

In order to send this information, we need your consent and agreement to the following items:

1. can use your email address or mobile phone number solely for the purpose of **Cliffside Labs** sending your estimated financial obligation. Text message data rates may apply. is not responsible for undelivered messages due to incorrect or illegible contact information.

2. will send you an email and/or text message containing a link to view your personalized Patient Letter that includes the test out-of-pocket estimate. The link is time-sensitive and will only be available for 72 hours from the time the message is sent. In order to view the estimate, you must click the link in the message.

3. If you take no action, **Cliffside Labs** will assume that you agree to move ahead with testing and will bill your health insurance. You can approve testing with insurance, switch to self-pay, or cancel the test via the link within the given 72-hour window. In turn, **Cliffside Labs** if receives your sample(s) and the billing method hasn't been changed, or the test hasn't been cancelled, we will move ahead with testing as ordered, and you will be responsible for any out-of-pocket costs for the completion of the test(s).

STOP Patient Signature

I hereby assign all rights and benefits under my health plan and all rights and obligations that I and my dependents have under my health plan to **Cliffside Labs** its assigned affiliates and authorized representatives for laboratory services furnished to me by **Cliffside Labs** I irrevocably designate, authorize and appoint **Cliffside Labs** or its assigned affiliates and their authorized representatives as my true and lawful attorney-in-fact for the purpose of submitting my claims, obtain a copy of my health plan document, Summary Plan Description, disclosure, appeal, litigation or other remedies in accordance with the benefits and rights under my health plan and in accordance with federal or state laws. If my health plan fails to abide by my authorization and makes payment directly to me, I agree to endorse the insurance check and forward it to **Cliffside Labs** immediately upon receipt. I hereby authorize **Cliffside Labs** its assigned affiliates and authorized representatives to contact me or my health Plan/administrator for billing or payment purposes by phone, text message, or email with the contact information that I have provided to **Cliffside Labs** in compliance with federal and state laws. **Cliffside Labs**, its assigned affiliates and their authorized representatives may release to my health plan administrator, my employer, and my authorized representative my personal health information for the purpose of procuring payment of **Cliffside Labs** and for all the laboratory services. I understand the acceptance of insurance does not relieve me from any responsibility concerning payment for laboratory services and that I am financially responsible for all charges whether or not they are covered by my insurance.

Signature of Patient or Patient Representative / Relationship to Patient Date:

STOP ORDERING PHYSICIAN SIGN HERE

Physician must only order tests that are medically necessary for the diagnosis or treatment of a patient

I attest that this test is medically necessary for the diagnosis or detection of a disease or disorder and that the results will be used in medical management and care decisions for the patient. Furthermore, all information on this Requisition Form is true to the best of my knowledge. I agree to provide the Care Plan notes and Letter of Intent for this order if the insurance requests the lab to gather the medical necessity for any reason

Ordering Physician Signature Date: